Article Information
Published By
History
- Received July 7, 2018
- Accepted November 30, 2018
- Published online February 1, 2019.
Copyright & Usage
Copyright: © 2019, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Author Information
- Xuelian Chen1,
- Lanying Ma2,
- Xi Wang1,
- Hongnan Mo1,
- Dawei Wu1,
- Bo Lan1,
- Dong Qu3,
- Hongtu Zhang4,
- Jing Huang1 and
- Binghe Xu1⇑
- 1State Key Laboratory of Molecular Oncology and Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology, Beijing 100021, China
- 2Department of Gastroenterology, Tumor Hospital Affiliated to Xinjiang Medical University, Tumor Hospital Affiliated to Xinjiang Medical University, Urumchi 830000, China
- 3Department of Diagnostic Radiology
- 4Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology, Beijing 100021, China
- Correspondence to: Binghe Xu, E-mail: xubinghe{at}csco.org.cn
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
- Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
- An eruption of dome-shaped, red papules
- Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy